Health Dictionary Find a Doctor

Serratia infection

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Serratia.

For patient information about Serratia infection, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: S. marsescens; S. entomophilia; S. ficaria; S. fonticola; S. grimesii; S. liquefaciens; S. odoriferae; S. plymuthica; S. proteamaculans; S. quinivorans; S. rubidaea; S. ureilytica; S. liquefaciens complex; pseudohemoptysis; prodigiosin; red pigment

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The first description of Serratia is attributed to Pythagoras in 6th centry B.C., where he reported “bloody” food coloration on food products. Serratia micro-organism was first isolated in 1819 in Italy by Bartolemeo Bizio. The characteristic red pigment produced by Serratia marcescens was first extracted by Dr. Kroft in 1902. Woodward and Clark described the first S. marcescens human infection in a patient with bronchiectasis in 1913.

Historical Perspective

  • The first description of Serratia is attributed to Pythagoras in 6th centry B.C., where he reported “bloody” food coloration on food products. The appearance of bloody food has been reported throughout history as ominous, inspirational, or prophesying.[1]
  • Serratia micro-organism was first isolated in 1819 in Italy by Bartolemeo Bizio. The organism was called Serratia in honor of Serafino Serrati, an Italian Physicist, and marcescens (Latin term for “to decay”) because of the pigment’s rapid decay.[1][2][3]
  • The characteristic red pigment produced by Serratia marcescens was first extracted by Dr. Kroft in 1902. The red pigment was initially referred to as prodigiosin.[4]
  • In 1913, Woodward and Clark described the first S. marcescens human infection in a patient with bronchiectasis.[5]
  • In 1957, the termpseudo-hemoptysis was coined by Robinson and Woolley to describe red sputum that is caused by the Serratia organism, not blood.[6]

References

  1. 1.0 1.1 Yu VL (1979). “Serratia marcescens: historical perspective and clinical review”. N Engl J Med. 300 (16): 887–93. doi:10.1056/NEJM197904193001604. PMID 370597.
  2. Bizio, B (1823). Lettera di Barolomeo al chiarissino canonico Angelo Belloni Sopra il fenomeno della polenta porporina. 30. Italy: Biblioteca Italiana o sia Giornale di Letteratira, Scienze e Arti. pp. 275–295.
  3. Merlino, CP (1924). “Bartolomeo Bizio’s letter to the most eminent priest, Angelo Bellani, concerning the phenomenon of the red-colored polenta”. J Bacteriol. 9: 527–543. |access-date= requires |url= (help)
  4. Kroft, E (1902). Beitrage zur Biologie des Bacillus prodigiosus und zum Chemischen Verhalten Seines Pigments (Thesis). Germany: University of Wurzberg.
  5. Woodward, HMM; Clarke, KB (1913). “A case of infection in man by the Bacterium prodigiosum”. Lancet. 1: 314–315. |access-date= requires |url= (help)
  6. ROBINSON W, WOOLLEY PB (1957). “Pseudohaemoptysis due to Chromobacterium prodigiosum”. Lancet. 272 (6973): 819. PMID 13417607.
Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Serratia may be classified according to the Serratia species into the following: S. marcescens (most common), S. fonticola, S. grimesii, S. liquefaciens sensu stricto, S. rubidaea, S. oderifera, S. plymuthica, and S. proteamaculans.

Classification

Serratia may be classified according to the Serratia species responsible for the infection into the following:

  • S. marcescens (> 90% of all Serratia infections in all age groups)
  • S. fonticola
  • S. grimesii
  • S. liquefaciens sensu stricto
  • S. rubidaea
  • S. oderifera
  • S. plymuthica
  • S. proteamaculans


  • Note that the S. liquefaciens complex is composed of 3 Serratia strains: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.
  • Additionally, 4 species of Serratia have been isolated but have not been reported to be clinically relevant. To view the comprehensive list of the 12 Serratia species, click here.

References

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Serratia may be transmitted by either direct contact or by ingestion of contaminated foods. Following transmission, Serratia colonizes and forms pathogenic biofilms. Serratia contains prodigiosin, a pigment that produces the characteristic dark-red or pale pink color. Prodigiosin is thought to contain immunosuppressive and anti-tumor activity. In addition, Serratia contains an LPS-containing outer membrane (endotoxin) and R-factors (responsible for antibiotic resistance). Following colonization, it is thought that Serratia may survive in the human host by altering macrophage function. In humans, Serratia is associated with the development of urinary tract infections, pneumonia, meningitis and cerebral abscess, ocular infections, endocarditis, intra-abdominal infection, osteomyelitis, otitis media, parotitis, and sepsis.

Pathophysiology

Transmission

  • Serratia is usually transmitted by direct contact, especially in healthcare settings during surgeries, instrumentation, and other procedures.
  • Serratia may also be transmitted by ingestion of contaminated foods, especially starchy foods.

Pathogenesis

Colonization and Formation of Biofilms

  • Following transmission, Serratia colonizes and forms pathogenic biofilms. Serratia biofilms may be produces on any surface.
  • Serratia contains an outer membrane that contains lipopolysaccharide (LPS). The LPS acts as an endotoxin, whereby when released the LPS over-stimulates the host defenses and cause them to undergo lethal endotoxic shock.
  • Serratia strains are usually resistant to several antibiotics because of the presence of R-factors (whose genes code for antibiotic resistance) on plasmids.
  • Serratia contains prodigiosin, a pigment that produces the characteristic dark-red or pale pink color. Prodigiosin is thought to contain immunosuppressive and anti-tumor activity, which may be required for the organism’s growth in the human host.[1][2]

Interference with Macrophage Function

  • It is thought that Serratia may survive in the human host by altering macrophage function.[3]
  • The exact mechanism by which Serratia infects the human host is poorly understood.

Associated Diseases

Serratia is associated with the development of the following diseases:

References

  1. Pérez-Tomás R, Viñas M (2010). “New insights on the antitumoral properties of prodiginines”. Curr Med Chem. 17 (21): 2222–31. PMID 20459382.
  2. Chang CC, Chen WC, Ho TF, Wu HS, Wei YH (2011). “Development of natural anti-tumor drugs by microorganisms”. J Biosci Bioeng. 111 (5): 501–11. doi:10.1016/j.jbiosc.2010.12.026. PMID 21277252.
  3. Remuzgo-Martínez S, Aranzamendi-Zaldunbide M, Pilares-Ortega L, Icardo JM, Acosta F, Martínez-Martínez L; et al. (2013). “Interaction of macrophages with a cytotoxic Serratia liquefaciens human isolate”. Microbes Infect. 15 (6–7): 480–90. doi:10.1016/j.micinf.2013.03.004. PMID 23524146.
Causes
This page is about microbiologic aspects of the organism(s).  For clinical aspects of the disease, see Serratia infection.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Serratia is a short, facultatively anaerobic, Gram-negative, rod-shaped bacteria of the Enterobacteriaceae family. Serratia species are ubiquitous opportunistic pathogens that are frequently present under damp conditions in food, plants, animals, soil, and household items.

Microbiological Characteristics

  • Serratia is a ubiquitous opportunistic pathogen that is frequently present under damp conditions in food, plants, animals, soil, and household items (e.g. bathroom tiles).
  • Serratia is a short, facultatively anaerobic, Gram-negative, rod-shaped bacteria of the Enterobacteriaceae family.
  • It is often associated with hospital-acquired infections.
  • Serratia contains enzymes that facilitate its survival under oxygenated conditions against reactive oxygen species. Enzymes include superoxide dismutase, catalase, and peroxidase.
  • Serratia has a unique thin cell wall that contains lipopolysaccharides (LPS) that does not resemble the LPS-containing cell walls of other Gram-negative bacteria.
  • Out of a total of 12 Serratia species (see Scientific Classification Table), 8 have been reported to be infectious in humans. To view the list of infectiuous Serratia species, click here.
  • Serratia is notoriously known for its antimicrobial resistance due to the presence of R-factor and efflux pumps.

Taxonomy

Serratia belongs to the following higher order taxa:

  • Bacteria (Domain); Proteobacteria (Phylum); Gamma Proteobacteria (Class); Enterobacteriales (Order); Enterobacteriaceae (Family); Serratia (Genus).

Species

The following is the list of Serratia species:

  • S. entomophila
  • S. ficaria
  • S. fonticola
  • S. grimesii
  • S. liquefaciens
  • S. marcescens
  • S. odoriferae
  • S. plymuthica
  • S. proteamaculans
  • S. quinivorans
  • S. rubidaea
  • S. ureilytica

Serratia marcescens

  • S. marcescens is a thin, motile (flagellated), non-septated, Gram-negative, facultatively anaerobic rod-shaped bacteria that can grow in temperatures ranging from 5–40 °C and in pH levels ranging from 5 to 9.
  • S. marcescens is able to perform casein hydrolysis, which facilitates the production of extracellular metalloproteases thought to function in cell-to-extracellular matrix interactions.
  • S. marcescens also exhibits tryptophan– and citrate-degradation. Pyruvic acid, an end-product of tryptophan degradation, and carbon, an end-product of citrate degradation, are then incorporated into metabolic processes.
  • S. marcescens produces a reddish-orange (bloody) pigment called prodigiosin. Not all strains, however, are able to produce prodigiosin. It is thought that prodigiosin is an antigen, and during an infection, the production of prodigiosin is limited to avoid the triggering of human immune responses.
  • Identification of the organism is commonly done via the following tests:
  • Methyl red test, which determines if a microorganism performs mixed-acid fermentation. Typically, S. marcescens results in a negative test due to the production of 2, 3-butanediol and ethanol.
  • Voges-Proskauer test, which determines the organism’s ability to convert pyruvatet to acetonin. Typically, S. marcescens results in a positive test.
  • Nitrate test, which determines the organism’s ability to produce nitrate products. Typically, S. marcescens results in a positive test.

Identification

The following table demonstrates the microbiological characteristics and a comprehensive list of techniques to identify S. marcescens:

Test Result[1]
Gram stain
Oxidase
Indole production
Methyl Red >70% –
Voges-Proskaeur +
Citrate (Simmons) +
Hydrogen sulfide production
Urea hydrolysis >70% –
Phenylalanine deaminase
Lysine decarboxylase +
Motility +
Gelatin hydrolysis, 22°C +
Acid from lactose
Acid from glucose +
Acid from maltose +
Acid from mannitol +
Acid from sucrose +
Nitrate reduction + (to nitrite)
Deoxyribonuclease, 25°C +
Lipase +
Pigment some biovars produce red
Catalase production (24h) +

Clinical Association

Clinically, Serratia may infect multiple organ systems. It may be responsible for urinary tract infection, pneumonia , osteomyelitis, meningitis, cerebral abscess formation, endocarditis, intra-abdominal infections, eye and tear duct infections (conjunctivitis, keratitis, endophthalmitis), otitis media, and rarely parotitis. To learn more about the clinical infection of Serratia, click here.

References

  1. Bergey’s Manuals of Determinative Bacteriology, by John G. Holt, 9th ed. Lippincott Williams & Wilkins, 15 January 1994. pp. 217
  2. “Public Health Image Library (PHIL)”.
  3. “Serratia marcescens – antibiogram”.
  4. “Bloody bread – Serratia marcescens in action”.
  5. “Serratia marcescens”.
  6. 6.0 6.1 “Serratia marcescen”.

Template:WikiDoc Sources


Template:WikiDoc Sources

Differentiating Serratia infection from Other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Serratia must be differentiated from other causes of urinary tract infection, pneumonia, endocarditis, meningitis, soft tissue infections, and Skin and soft-tissue infectionswound infections. Differential diagnoses include other infections, such as infections caused by Staphylococcus, Streptococcus, E. coli, Pseudomonas, Haemophilus, tuberculosis, syphilis, and other sexually transmitted infections, as well as other non-infectious systemic diseases, such as tumors, vasculitides, and chemical poisoning.

Differential Diagnosis

Urinary Tract Infection

Serratia urinary tract infection (UTI) must be differentiated from other causes of abdominal discomfort, dysuria, hematuria, pyuria, and/or polyuria, such as:

  • Other causes of UTI

Pneumonia

Serratia pneumonia must be differentiated from other causes of fever, chest pain, productive cough, dyspnea, and blood per sputum, such as:

  • Other infectious causes of pneumonia:

Intra-abdominal Infection

Serratia intra-abdominal infection must be differentiated from other causes of abdominal pain and fever, such as:

  • Other intra-abdominal infections

Meningitis / Cerebral Abscess

Serratia meningitis / cerebral abscess must be differentiated from other causes of headache, fever, and altered mental status, such as:

Endocarditis

Serratia endocarditis must be differentiated from other causes of fever, petechiae, and abnormal heart murmurs, such as:

  • Other causes of infectious endocarditis

References

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The annual incidence of Serratia infection is approximately 1 per 100,000 individuals. Serratia may infect individuals of all age groups, but infections in infants and young children are more common. Males are slightly more predisposed to the development of Serratia infections with a male to female ratio of 1.3 to 1.

Epidemiology and Demographics

Incidence

  • The annual incidence of Serratia infection is approximately 1 per 100,000 individuals.[1]
  • Approximately half of all Serratia infections are community-acquired.
  • Less than 2% of all hospital-acquired infections are caused by Serratia.[1]

Age

  • Serratia may infect individuals of all age groups.
  • Serratia commonly infects infants and young children.

Gender

  • Males are slightly more predisposed to the development of Serratia infections.
  • The male to female ratio for Serratia infection is approximately 1.3 to 1.[1]

References

  1. 1.0 1.1 1.2 Engel HJ, Collignon PJ, Whiting PT, Kennedy KJ (2009). “Serratia sp. bacteremia in Canberra, Australia: a population-based study over 10 years”. Eur J Clin Microbiol Infect Dis. 28 (7): 821–4. doi:10.1007/s10096-009-0707-7. PMID 19194731.
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Common risk factors for the development of Serratia infection include recent surgery (head, abdominal, ocular, genitourinary, or cardiac valve replacement), recent instrumentation, recent procedures (bronchoscopy, urinary catheterization), mechanical ventilation, recent trauma or burn, blood transfusions, diabetes mellitus, use of contact lenses, and IV drug use.[1][2][3][4][5][6]

Risk Factors

Risk factors for the development of Serratia infection include:[1][2][3][4][5][6]

  • Parenteral feeding
  • Mechanical ventilation
  • Bronchoscopy
  • Head trauma
  • Recent head, abdominal, ocular, or genitourinary surgery
  • Surgical scar
  • Recent burn
  • Recent cellulitis, phlebitis, or other skin infection
  • Cardiac valve replacement
  • Blood transfusions
  • Catheter placement
  • Diabetes mellitus
  • Urinary tract obstruction
  • IV Drug use
  • Use of contact lenses

References

  1. 1.0 1.1 Ostrowsky BE, Whitener C, Bredenberg HK, Carson LA, Holt S, Hutwagner L; et al. (2002). “Serratia marcescens bacteremia traced to an infused narcotic”. N Engl J Med. 346 (20): 1529–37. doi:10.1056/NEJMoa012370. PMID 12015392.
  2. 2.0 2.1 Sunenshine RH, Tan ET, Terashita DM, Jensen BJ, Kacica MA, Sickbert-Bennett EE; et al. (2007). “A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy”. Clin Infect Dis. 45 (5): 527–33. doi:10.1086/520664. PMID 17682984.
  3. 3.0 3.1 Horcajada JP, Martínez JA, Alcón A, Marco F, De Lazzari E, de Matos A; et al. (2006). “Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication”. Infect Control Hosp Epidemiol. 27 (7): 774–7. doi:10.1086/504445. PMID 16807859.
  4. 4.0 4.1 Mills J, Drew D (1976). “Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse”. Ann Intern Med. 84 (1): 29–35. PMID 1106290.
  5. 5.0 5.1 Pinna A, Usai D, Sechi LA, Carta A, Zanetti S (2011). “Detection of virulence factors in Serratia strains isolated from contact lens-associated corneal ulcers”. Acta Ophthalmol. 89 (4): 382–7. doi:10.1111/j.1755-3768.2009.01689.x. PMID 19845561.
  6. 6.0 6.1 Friedman ND, Peterson NB, Sumner WT, Alexander BD (2003). “Spontaneous dermal abscesses and ulcers as a result of Serratia marcescens”. J Am Acad Dermatol. 49 (2 Suppl Case Reports): S193–4. doi:10.1067/mjd.2003.312. PMID 12894121.
Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Screening for Serratia infection among asymptomatic individuals is not recommended.

Screening

Screening for Serratia infection among asymptomatic individuals is not recommended.

References

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Following transmission, approximately 30% to 50% of individuals do not develop any clinical manifestations. The incubation period of Serratia is not known, but is thought to range from several days to several weeks. Clinical manifestations of Serratia depend on the location of the colonization (e.g. respiratory tract, urinary tract, meninges, heart valves). Complications and prognosis are dependent to the site of Serratia infection.

Natural History

  • Following transmission, approximately 30% to 50% of individuals do not develop any clinical manifestations.
  • The incubation period of Serratia is not known, but is thought to range from several days to several weeks.
  • Clinical manifestations of Serratia depend on the location of the colonization (e.g. respiratory tract, urinary tract, meninges, heart valves)
  • Clinical manifestations are usually non-specific and include fever and typical signs and symptoms of the clinical disease.
  • If left untreated, patients with Serratia infection typically progress and develop complications.

Complications

Complications of Serratia infection depend on the clinical syndrome. Complications may include complications of the following disease:

Prognosis

  • With prompt and adequate treatment, patients with Serratia recover without any long-term sequelae.
  • Prognosis of Serratia infection is generally good in urinary tract infections, pneumonia, and local wound infections.
  • The prognosis is poorer when Serratia causes meningitis or endocarditis, given the prognosis of the clinical syndromes themselves.

References

Diagnosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray

Treatment

Treatment

Medical Therapy | Prevention | Cost-Effectiveness of therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

External Links

Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH